JGC
RVMD icon

J. Goldman & Co’s Revolution Medicines RVMD Stock Holding History

J. Goldman & Co’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-67,500
Closed -$1.87M – 459
2023
Q3 		$1.87M Buy
+67,500
New +$2M 0.07% 208

Other funds holding RVMD

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

J. Goldman & Co's RVMD Position: Q1 2026 in Review

J. Goldman & Co sold out of Revolution Medicines (RVMD) in Q1 2026, closing a stake of 10,179 shares — an estimated $811K sold.

J. Goldman & Co first reported a position in RVMD in Q3 2023 and held it in 6 quarters. The position peaked at $1.15M in Q4 2024. 512 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

  • J. Goldman & Co reported no remaining Revolution Medicines position as of Q1 2026 after selling out during the quarter.
  • J. Goldman & Co sold 10,179 Revolution Medicines shares in Q1 2026, an estimated $811K.
  • J. Goldman & Co first reported a position in Revolution Medicines in Q3 2023 and held it in 6 quarters.
  • J. Goldman & Co's Revolution Medicines position peaked at $1.15M in Q4 2024.
  • 512 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.